RxDoctor Payments Data

Yan Lin He, DO

Internal Medicine · Longview, WANPI 1538470331

Payments from drug & device makers

$878in general payments, 2019–2025

Across 54 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$207
  • Pfizer$114
  • Johnson & Johnson$109
  • Amarin Pharma, Inc.$67
  • Merck$61
  • Lilly USA, LLC$51
  • plus $270 from 9 others

What the payments were for

  • Food & beverage$878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$878 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$36,645
Medicare patients
16
Services billed
1,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PradaxaDabigatran Etexilate Mesylate170$45,319
OzempicSemaglutide60$44,404
Spiriva RespimatTiotropium Bromide48$33,926
XareltoRivaroxaban35$28,837
JardianceEmpagliflozin53$20,016
Humulin NInsulin Nph Human Isophane104$17,486
Wixela InhubFluticasone Propion/Salmeterol49$11,724
Atorvastatin Calcium918$10,318
Gabapentin341$8,748
Insulin Glargine-Yfgn60$8,326
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,235
Levothyroxine Sodium477$8,133
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen322$7,768
Lisinopril622$7,343
Humulin RInsulin Regular, Human53$6,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimPradaxa, Spiriva Respimat, Jardiance, Stiolto Respimat$207$107,496282 claims
Johnson & JohnsonXarelto$109$28,83735 claims
Lilly USA, LLCHumulin N, Humulin 70-30, Humalog$51$25,409144 claims
GSKShingrix$23$5,60028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Longview

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →